Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 May 6;8(2):99-102.
doi: 10.4292/wjgpt.v8.i2.99.

5-Aminosalicylates to maintain remission in Crohn's disease: Interpreting conflicting systematic review evidence

Morris Gordon  1
Affiliations
Editorial

5-Aminosalicylates to maintain remission in Crohn's disease: Interpreting conflicting systematic review evidence

Morris Gordon. World J Gastrointest Pharmacol Ther. .

Abstract

5-Aminosalicylates are a class of anti-inflammatory agents that have been used for decades in inflammatory bowel disease. Whilst they are first line for induction and an option for maintenance of remission in ulcerative colitis, the picture in Crohn's disease is variable. For maintenance of remission, key Cochrane systematic reviews have found conflicting results between the medical and surgical induced contexts. In this piece, the possible reasons for this are considered. It is proposed that clinicians should consider 5-aminosalicylates agents an option to maintain remission post-surgery. Future primary research is needed in the medical induced remission setting which considers the length of remission on enrolment and endoscopic or histological disease scores. Additionally, secondary research to rank the various treatment options in the post-surgical setting could be achieved through the use of network meta-analysis and will guide policy makers in the future.

Keywords: 5-Aminosalicylate; Cochrane; Crohn’s disease; Inflammatory bowel disease; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.

References

    1. Svartz N. Salazyoprin, a new sulfanilamide preparation: A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Med Scand. 1942;110:557–590.
    1. Mulrow CD. The medical review article: state of the science. Ann Intern Med. 1987;106:485–488. - PubMed
    1. Oxman AD, Guyatt GH. Guidelines for reading literature reviews. Can Med Assoc J. 1988;138:697–703. - PMC - PubMed
    1. Mulrow CD, Oxman ADeds. Cochrane Collaboration handbook. In: Cochrane Library., editor. Issue 4. Oxford: Update Software; 1997.
    1. Cochrane Collaboration. What is Cochrane evidence and how can it help you? Available from: http://www.cochrane.org/what-is-cochrane-evidence.

Publication types